Analyst favorites — what the screen found 2026-09-22

Screen Highlights: 39 Companies Pass the Strong-Buy Leaning Consensus Test

A total of 39 companies out of a pool of 2167 pass the "Analyst favorites" screen on September 21, 2026, defined by a strong-buy-leaning consensus from real coverage. Notably, Elevance Health (ELV) and EPRX both receive an analyst rating of 1.0, indicating a strong buy signal from multiple analysts. However, ELV's market capitalization dwarfs that of the other companies at $88.60B compared to EPRX’s $571.20M.

This screen identifies a diverse group of companies with similar analyst sentiment but does not establish their actual investment worthiness. The strong buy signal is merely a starting point, reflecting historical analyst views on these firms. Factors such as underlying fundamentals, market conditions, and future performance are not accounted for by this filter alone.